RTI Biologics Inc. (RTIX) reported fourth-quarter net income of $1.489 million or $0.03 per share compared to a net loss of $102.515 million or $1.89 per share last year.
On average, 8 analysts polled by Thomson Reuters expected the company to report profit of $0.04 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenues increased to $41.960 million from $37.363 million last year. Analysts expected revenue of $43.20 million for the quarter.
The company expects full year revenues for 2010 to increase between 5% and 7% on a constant currency basis. Assuming foreign currency exchange rates remain near year-end 2009 levels, the company estimates that foreign currency translation adjustments will increase revenues by approximately 1% for the full year 2010, resulting in reported revenue growth between 6% and 8%, or between $174.5 million and $177.5 million. Full year earnings per share are expected to be in the range of $0.15 to $0.17, based on 55.7 million fully diluted shares outstanding.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.